Efficient gene transfer to airway epithelium using recombinant Sendai virus
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Clinical studies of gene therapy for cystic fibrosis (CF) suggest that the key problem is the efficiency of gene transfer to the airway epithelium. The availability of relevant vector receptors, the transient contact time between vector and epithelium, and the barrier function of airway mucus contribute significantly to this problem. We have recently developed recombinant Sendai virus (SeV) as a new gene transfer agent. Here we show that SeV produces efficient transfection throughout the respiratory tract of both mice and ferrets in vivo, as well as in freshly obtained human nasal epithelial cells in vitro. Gene transfer efficiency was several log orders greater than with cationic liposomes or adenovirus. Even very brief contact time was sufficient to produce this effect, and levels of expression were not significantly reduced by airway mucus. Our investigations suggest that SeV may provide a useful new vector for airway gene transfer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although both methods have low reprogramming efficiency, Sendai virus-mediated reprogramming has been used for several clinical applications, notably, in cystic fibrosis, the AIDS vaccine, and other iPSC replacement therapies [29,30,31,32,33].”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [29]
Citations
Cites
Fuerst, T. R., Niles, E. G., Studier, F. W., & Moss, B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.21.8122 · Cited by 2,089 · cited 1×
“Recombinant SeVs were constructed and propagated as previously describe”
MethodLiposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis
Caplen, N. J., Alton, E. W. F. W., Mddleton, P. G., Dorin, J. R., Stevenson, B. J., Gao, X., Durham, S. R., Jeffery, P. K., Hodson, M. E., Coutelle, C., et al. (1995) · Nature Medicine · doi:10.1038/nm0195-39 · Cited by 711
Zabner, J., Couture, L. A., Gregory, R. J., Graham, S. M., Smith, A. E., & Welsh, M. J. (1993) · Cell · doi:10.1016/0092-8674(93)80063-k · Cited by 681
Submucosal glands are the predominant site of CFTR expression in the human bronchus
Engelhardt, J. F., Yankaskas, J. R., Ernst, S. A., Yang, Y., Marino, C. R., Boucher, R. C., Cohn, J. A., & Wilson, J. M. (1992) · Nature Genetics · doi:10.1038/ng1192-240 · Cited by 653 · cited 1×
“2E ), the predominant site of CFTR expression in the human bronchu”
BackgroundLee, E. R., Marshall, J., Siegel, C. S., Jiang, C., Yew, N. S., Nichols, M. R., Nietupski, J. B., Ziegler, R. J., Lane, M. B., Wang, K. X., et al. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.14-1701 · Cited by 443 · cited 1×
“, or the plasmid pCMV-luc complexed to GL-67/DOPE/DMPE-PEG 5000 (80 μg DNA/mouse) were placed as a single 100 μl bolus into the nasal cavity of male BALB/c mice (six to eight weeks), and the solution was sniffed into the lung”
MethodEfficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis
Johnson, L. G., Olsen, J. C., Sarkadi, B., Moore, K. L., Swanstrom, R., & Boucher, R. C. (1992) · Nature Genetics · doi:10.1038/ng0992-21 · Cited by 439 · cited 1×
“Laboratory studies suggest that correction of the CF chloride defect can be achieved by introducing ∼6–10% of corrected cells overexpressing CFTR into a CF monolaye”
BackgroundAlton, E., Stern, M., Farley, R., Jaffe, A., Chadwick, S., Phillips, J., Davies, J., Smith, S., Browning, J., Davies, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06532-5 · Cited by 435
Porteous, D., Dorin, Jr., McLachlan, G., Davidson-Smith, H., Davidson, H., Stevenson, B., Carothers, A., Wallace, W., Moralee, S., Hoenes, C., et al. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300390 · Cited by 324
Specific gangliosides function as host cell receptors for Sendai virus.
Markwell, M. A., Svennerholm, L., & Paulson, J. C. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5406 · Cited by 259 · cited 1×
“The receptor for SeV is sialic acid bound to gangliosides, present on most cell types, including the apical surface of the conducting airway”
BackgroundExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo
Ferrari, S., Moro, E., Pettenazzo, A., Behr, J., Zacchello, F., & Scarpa, M. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300503 · Cited by 256 · cited 1×
“Two days post infection, ferrets were killed and the lungs fixed by intratracheal perfusion of fixative solution, excised en bloc, processed, and stained with X-Gal as described by Ferrari and colleague”
Method
Cited by
FUSAKI, N., BAN, H., NISHIYAMA, A., SAEKI, K., & HASEGAWA, M. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.348 · Cited by 1,411
Self-citationNALT- versus PEYER'S-patch-mediated mucosal immunity
Kiyono, H., & Fukuyama, S. (2004) · Nature Reviews Immunology · doi:10.1038/nri1439 · Cited by 745
“www.nature.com/reviews/immunol R E V I E W S guides antigen to the mucosal epithelium, because the Sendai virus itself uses this fusion protein for the invasion of respiratory epithelial cells 74 .”
BackgroundZhang, L., Peeples, M. E., Boucher, R. C., Collins, P. L., & Pickles, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.11.5654-5666.2002 · Cited by 581
“Sendai virus vectors have been shown to infect ciliated cells of the rodent airway (43), but the efficiency with which this rodent virus infects HAE cells remains to be determined.”
BackgroundKobinger, G. P., Weiner, D. J., Yu, Q.-C., & Wilson, J. M. (2001) · Nature Biotechnology · doi:10.1038/85664 · Cited by 307
Cu, Y., & Saltzman, W. M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8001254 · Cited by 267
Masaki, I., Yonemitsu, Y., Yamashita, A., Sata, S., Tanii, M., Komori, K., Nakagawa, K., Hou, X., Nagai, Y., Hasegawa, M., et al. (2002) · Circulation Research · doi:10.1161/01.res.0000019540.41697.60 · Cited by 240
Extracellular barriers in respiratory gene therapy
Sanders, N., Rudolph, C., Braeckmans, K., De Smedt, S. C., & Demeester, J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.09.011 · Cited by 229
“The ex vivo sheep trachea model has also been used to evaluate the effect of normal (sheep) respiratory mucus on the gene transfer capacity of lipoplexes, polyplexes, sendai and adenoviral vectors [66,67].”
MethodZhang, L., Button, B., Gabriel, S. E., Burkett, S., Yan, Y., Skiadopoulos, M. H., Dang, Y. L., Vogel, L. N., McKay, T., Mengos, A., et al. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000155 · Cited by 194
“Lentiviral-based vectors pseudotyped with Ebola, influenza virus, baculovirus, Sendai, or SARS-CoV envelope proteins efficiently transduce airway epithelial cells in vitro and murine airways in vivo [48] [49] [50] [51] [52] [53] , suggesting that combining useful envelope glycoproteins with the potential longer durati…”
BackgroundCurrent prospects for mRNA gene delivery
Yamamoto, A., Kormann, M., Rosenecker, J., & Rudolph, C. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.016 · Cited by 190
Miyamoto, K., Akiyama, M., Tamura, F., Isomi, M., Yamakawa, H., Sadahiro, T., Muraoka, N., Kojima, H., Haginiwa, S., Kurotsu, S., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2017.11.010 · Cited by 189
“SeV vectors have been studied for their potential applications in clinical studies of gene therapy for cystic fibrosis, critical limb ischemia, vaccines for HIV, and other areas (Ferrari et al., 2007; Matsumoto et al., 2016; Takeda et al., 2008; Yonemitsu et al., 2000).”
BackgroundImmunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
Medrano, R. F. V., Hunger, A., Mendonça, S. A., Barbuto, J. A. M., & Strauss, B. E. (2017) · Oncotarget · doi:10.18632/oncotarget.19531 · Cited by 182
“Another emerging viral vector is the Sendai virus due to its high transduction efficiency ex vivo and in vivo, augmented capacity to trigger antitumor immune responses and elicit DC maturation [345, 346].”
BackgroundGene therapy progress and prospects: cystic fibrosis
Griesenbach, U., Geddes, D. M., Alton, E. W. F. W., & on behalf of the UK Cystic Fibrosis Gene Therapy Consortium (2006) · Gene Therapy · doi:10.1038/sj.gt.3302809 · Cited by 175
Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis
Ferrari, S., Geddes, D. M., & Alton, E. W. F. W. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00145-x · Cited by 166
Nakanishi, M., & Otsu, M. (2012) · Current Gene Therapy · doi:10.2174/156652312802762518 · Cited by 147
“In addition to the lung/airway epithelium [25], a recombinant SeV vector can induce strong ex-gene expression in the cardiovascular system [26], in retinal epithelium [27], in hepatocytes [12], in colonic epithelium [28], in neurons [24], in dendritic cells [29] and in human hematopoietic stem cells [30].”
BackgroundTransport of Polymeric Nanoparticle Gene Carriers in Gastric Mucus
Dawson, M., Krauland, E., Wirtz, D., & Hanes, J. (2004) · Biotechnology Progress · doi:10.1021/bp0342553 · Cited by 142
Toward Gene Therapy for Cystic Fibrosis Using a Lentivirus Pseudotyped With Sendai Virus Envelopes
Mitomo, K., Griesenbach, U., Inoue, M., Somerton, L., Meng, C., Akiba, E., Tabata, T., Ueda, Y., Frankel, G. M., Farley, R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.13 · Cited by 135
Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy
Al Abbar, A., Ngai, S. C., Nograles, N., Alhaji, S. Y., & Abdullah, S. (2020) · BioResearch Open Access · doi:10.1089/biores.2019.0046 · Cited by 134
Electroporation as a method for high-level nonviral gene transfer to the lung
Dean, D. A., Machado-Aranda, D., Blair‐Parks, K., Yeldandi, A. V., & Young, J. L. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302053 · Cited by 147
Nakao, I., Kanaji, S., Ohta, S., Matsushita, H., Arima, K., Yuyama, N., Yamaya, M., Nakayama, K., Kubo, H., Watanabe, M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6262 · Cited by 130
“To do so, we established the Slc26a4 gene-expressing Sendai virus vector, because this vector possesses highly efficient gene transfer capability into airway epithelial cells in vivo (38).”
BackgroundBarriers to inhaled gene therapy of obstructive lung diseases: A review
Kim, N., Duncan, G. A., Hanes, J., & Suk, J. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.031 · Cited by 118
“Incorporating components from the capsid of other respiratory viruses, such as bocavirus [112], baculovirus [9] and sendai virus (SeV) [9, 130, 306], is also a common strategy to introduce lung tropism.”
Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium
Ferrari, S., Kitson, C., Farley, R., Steel, R. M., Marriott, C., Parkins, D., Scarpa, M., Wainwright, B. J., Evans, M., Colledge, W. H., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301525 · Cited by 120
Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats
Ikeda, Y., Yonemitsu, Y., Kataoka, C., Kitamoto, S., Yamaoka, T., Nishida, K.-I., Takeshita, A., Egashira, K., & Sueishi, K. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00919.2001 · Cited by 114
The CF mouse: an important tool for studying cystic fibrosis
Davidson, D. J., & Dorin, J. R. (2001) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399401002551 · Cited by 115
Cieślar‐Pobuda, A., Knoflach, V., Ringh, M. V., Stark, J., Likus, W., Siemianowicz, K., Ghavami, S., Hudecki, A., Green, J. L., & Łoś, M. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.04.017 · Cited by 128
iPSC Preparation and Epigenetic Memory: Does the Tissue Origin Matter?
Scesa, G., Adami, R., & Bottai, D. (2021) · Cells · doi:10.3390/cells10061470 · Cited by 110
Yamashita, A., Yonemitsu, Y., Okano, S., Nakagawa, K., Nakashima, Y., Irisa, T., Iwamoto, Y., Nagai, Y., Hasegawa, M., & Sueishi, K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.450 · Cited by 119
“To determine the exact role of overexpression of FGF-2 in the RA joint in vivo, we conducted in vivo gene transfer of FGF-2 using a recombinant Sendai virus vector (SeV), which has shown effective transfer potential to various organs (27, 28).”
MethodAssessment of F/HN-Pseudotyped Lentivirus as a Clinically Relevant Vector for Lung Gene Therapy
Griesenbach, U., Inoue, M., Meng, C., Farley, R., Chan, M., Newman, N. K., Brum, A., You, J., Kerton, A., Shoemark, A., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201206-1056oc · Cited by 108
“SeV shares high sequence homology with human parainfluenza virus and preexisting immunity may be a factor.”
InfluentialGeneration of Integration-free and Region-Specific Neural Progenitors from Primate Fibroblasts
Lü, J., Liu, H., Huang, C. T.-L., Chen, H., Du, Z., Liu, Y., Sherafat, M. A., & Zhang, S. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.004 · Cited by 107
“SeV-based vector has been used in clinical gene therapy for cystic fibrosis (Ferrari et al., 2007; Yonemitsu et al., 2000) and vaccine delivery (Takeda et al.”
MethodAll Roads Lead to Induced Pluripotent Stem Cells: The Technologies of iPSC Generation
Hu, K. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0620 · Cited by 105
“Although SeV is not pathogenic to human, it naturally infects the airway epithelium [84], and, therefore, extreme care should be exercised in handing packaged virions when oncogenes such as c-Myc and Klf4 are installed in this vector.”
BackgroundOnimaru, M., Yonemitsu, Y., Tanii, M., Nakagawa, K., Masaki, I., Okano, S., Ishibashi, H., Shirasuna, K., Hasegawa, M., & Sueishi, K. (2002) · Circulation Research · doi:10.1161/01.res.0000043281.66969.32 · Cited by 96
Miyoshi, K., Wakioka, T., Nishinakamura, H., Kamio, M., Yang, L., Inoue, M., Hasegawa, M., Yonemitsu, Y., Komiya, S., & Yoshimura, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207759 · Cited by 94
“A virus titer was determined by a hemagglutination assay using chicken red blood cells (Yonemitsu et al., 2000), and the virus was then stored at 801C until use.”
BackgroundMethodMacArthur, C. C., Fontes, A., Ravinder, N., Kuninger, D., Kaur, J., Bailey, M., Taliana, A., Vemuri, M. C., & Lieu, P. T. (2012) · Stem Cells International · doi:10.1155/2012/564612 · Cited by 91
“Sendai virus vector has been considered for clinical studies of gene therapy for cystic fibrosis [16, 17] and vaccine delivery [18].”
BackgroundUsing magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo
Xenariou, S., Uta Griesenbach, D., Ferrari, S., Dean, P., Scheule, R. K., Cheng, S. H., Geddes, D. M., Plank, C., & Alton, E. W. F. W. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302803 · Cited by 87
Sendai virus, the mouse parainfluenza type 1: A longstanding pathogen that remains up-to-date
Faísca, P., & Desmecht, D. J.-M. (2006) · Research in Veterinary Science · doi:10.1016/j.rvsc.2006.03.009 · Cited by 87
Sendai virus vectors as an emerging negative‐strand RNA viral vector system
Bitzer, M., Armeanu, S., Lauer, U. M., & Neubert, W. J. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.426 · Cited by 85
“SeVVs have been successfully employed in studies analyzing gene transfer to human (nasal epithelial cells, saphenous vein explants, primary hepatocytes, CD34+-umbilical cord derived cells) [32,34,42], non-human primate (nasal mucosa of macaques, African green monkey and chimpanzee) [8,9], mouse (muscle, upper and lowe…”
BackgroundMethodInfluentialStonebraker, J. R., Wagner, D., Lefensty, R. W., Burns, K. A., Gendler, S. J., Bergelson, J. M., Boucher, R. C., O’Neal, W. K., & Pickles, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.24.13755-13768.2004 · Cited by 90
Fujihara, A., Kurooka, M., Miki, T., & Kaneda, Y. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0351-y · Cited by 81
Masaki, I., Yonemitsu, Y., Komori, K., Ueno, H., Nakashima, Y., Nakagawa, K., Fukumura, M., Kato, A., Hasan, M. K., Nagai, Y., et al. (2001) · The FASEB Journal · doi:10.1096/fj.00-0460fje · Cited by 81
“A brief vector interaction resulted in similar transfection activity to that of continuous perfusion in the mouse nose (18).”
BackgroundRecombinant Sendai viruses expressing different levels of a foreign reporter gene
Tokusumi, T., Iida, A., Hirata, T., Kato, A., Nagai, Y., & Hasegawa, M. (2002) · Virus Research · doi:10.1016/s0168-1702(02)00047-3 · Cited by 80
Sakaue, G., Hiroi, T., Nakagawa, Y., Someya, K., Iwatani, K., Sawa, Y., Takahashi, H., Honda, M., Kunisawa, J., & Kiyono, H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.495 · Cited by 79
“It was shown that HVJ-liposome directly attaches to the cell membrane using envelope glycoproteins, the so-called fusion proteins of the Sendai virus (27–29), which function during natural infection via the respiratory epithelium (30, 31).”
BackgroundViral and Synthetic RNA Vector Technologies and Applications
Schott, J. W., Morgan, M., Galla, M., & Schambach, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.143 · Cited by 76
Kobayashi, M., Iida, A., Ueda, Y., & Hasegawa, M. (2003) · Journal of Virology · doi:10.1128/jvi.77.4.2607-2614.2003 · Cited by 76
SOC1 inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein
Kamio, M., Yoshida, T., Ogata, H., Douchi, T., Nagata, Y., Inoue, M., Hasegawa, M., Yonemitsu, Y., & Yoshimura, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207453 · Cited by 85
Gene Transfer of the Na+,K+-ATPase β1 Subunit Using Electroporation Increases Lung Liquid Clearance
Machado-Aranda, D., Adir, Y., Young, J. L., Briva, A., Budinger, G. R. S., Yeldandi, A. V., Sznajder, J. I., & Dean, D. A. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200403-313oc · Cited by 71
Gene therapy for cystic fibrosis
Davies, J. C., Geddes, D. M., & Alton, E. W. F. W. (2001) · The Journal of Gene Medicine · doi:10.1002/jgm.200 · Cited by 70
“With regard to efficiency, much research is going into both overcoming barriers to gene transfer and vector design, including viral pseudotyping, the development of newer generation cationic liposomes, and the use of novel viral agents capable of naturally high levels of transfection such as Sendai virus [86].”
BackgroundIorio, E. D., Barbaro, V., Ferrari, S., Ortolani, C., Luca, M. D., & Pellegrini, G. (2006) · Microscopy Research and Technique · doi:10.1002/jemt.20375 · Cited by 68
“Evaluation and quantification of protein and nucleicacid signals from in vivo tissues by Q-FIHC could therefore replace traditional histological techniques, such as microscopic point counting (Yonemitsu et al., 2000), currently used to assess the amount of staining in sectioned tissues.”
MethodTanii, M., Yonemitsu, Y., Fujii, T., Shikada, Y., Kohno, R.-I., Onimaru, M., Okano, S., Inoue, M., Hasegawa, M., Onohara, T., et al. (2005) · Circulation Research · doi:10.1161/01.res.0000197842.38758.45 · Cited by 68
Pulmonary Gene Delivery Using Polymeric Nonviral Vectors
Merkel, O. M., Zheng, M., Debus, H., & Kissel, T. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200296q · Cited by 66
Inoue, M., Tokusumi, Y., Ban, H., Kanaya, T., Shirakura, M., Tokusumi, T., Hirata, T., Nagai, Y., Iida, A., & Hasegawa, M. (2003) · Journal of Virology · doi:10.1128/jvi.77.11.6419-6429.2003 · Cited by 66
“These properties make SeV vectors very promising for application to gene therapy via the expression of therapeutic genes and vaccine antigens (24, 30, 40, 45, 48).”
BackgroundTsutsumi, N., Yonemitsu, Y., Shikada, Y., Onimaru, M., Tanii, M., Okano, S., Kaneko, K., Hasegawa, M., Hashizume, M., Maehara, Y., et al. (2004) · Circulation Research · doi:10.1161/01.res.0000126925.66005.39 · Cited by 66
Gene Therapy Progress and Prospects: Cystic fibrosis
Griesenbach, U., Ferrari, S., Geddes, D. M., & Alton, E. W. F. W. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301791 · Cited by 81
Inoue, M., Tokusumi, Y., Ban, H., Kanaya, T., Tokusumi, T., Nagai, Y., Iida, A., & Hasegawa, M. (2003) · Journal of Virology · doi:10.1128/jvi.77.5.3238-3246.2003 · Cited by 65
“Indeed, it has been shown to mediate effective gene transfer to the respiratory tracts of mice, ferrets, and sheep (36); the vascular system of rabbits (21); and the skeletal muscle (29) as well as the central nervous system (19) of rats.”
BackgroundRNA-Based Tools for Nuclear Reprogramming and Lineage-Conversion: Towards Clinical Applications
Bernal, J. A. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9494-8 · Cited by 65
“in a gene therapy setting for different diseases such as cystic fibrosis [77, 90], critical limb ischemia [91], and vaccines for AIDS [92, 93].”
BackgroundSendai virus-mediated CFTR gene transfer to the airway epithelium
Ferrari, S., Griesenbach, U., Iida, A., Farley, R., Wright, A. M., Zhu, J., Munkonge, F. M., Smith, S. N., You, J., Ban, H., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302991 · Cited by 63
Self-citationShibata, S., Okano, S., Yonemitsu, Y., Onimaru, M., Sata, S., 竹下, 寛., Inoue, M., Zhu, T., Hasegawa, M., Moroi, Y., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3564 · Cited by 61
“rSeVs were constructed as described previously (10).”
BackgroundMethodKunisawa, J., Nakagawa, S., & Mayumi, T. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00214-9 · Cited by 67
Reverse genetics of negative-stranded RNA viruses: A global perspective
Walpita, P., & Flick, R. (2005) · FEMS Microbiology Letters · doi:10.1016/j.femsle.2005.01.046 · Cited by 61
“Gene transfer to murine lung epithelium mediated by a replication competent SeV vector appeared also to be effective [74].”
BackgroundCarvalho, M. A. B. R., Sepodes, B. M. N., & Martins, A. P. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00182 · Cited by 75
“Direct airway drug delivery encounters a number of challenges such as low availability of relevant vector receptors, short contact time between vector and epithelium, and the barrier function of airway mucus (123).”
BackgroundOno, M., Hamada, Y., Horiuchi, Y., Matsuo‐Takasaki, M., Imoto, Y., Satomi, K., Arinami, T., Hasegawa, M., Fujioka, T., Nakamura, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042855 · Cited by 61
“SeV is an important respiratory pathogen of rats and mice, and it has been reported that SeV vectors efficiently transduce the respiratory tract of mice as well as humans [11].”
BackgroundShirakura, M., Inoue, M., Fujikawa, S., Washizawa, K., Komaba, S., Maeda, M., Watabe, K., Yoshikawa, Y., & Hasegawa, M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302224 · Cited by 59
Park, A., Hong, P. W.-P., Won, S. T., Thibault, P. A., Vigant, F., Oguntuyo, K. Y., Taft, J. D., & Lee, B. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.57 · Cited by 68
Kunisawa, J., Nakanishi, T., Takahashi, I., Okudaira, A., Tsutsumi, Y. M., Katayama, K., Nakagawa, S., Kiyono, H., & Mayumi, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1406 · Cited by 64
“In addition, it is well known that Sendai virus naturally infects via mucosal epithelia (16, 17).”
BackgroundLung transplantation: infection, inflammation, and the microbiome
Nakajima, T., Palchevsky, V., Perkins, D. L., Belperio, J. A., & Finn, P. W. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0249-9 · Cited by 62
“airway fibroplasia [165–168].”
VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B
Onimaru, M., Yonemitsu, Y., Fujii, T., Tanii, M., Nakano, T., Nakagawa, K., Kohno, R.-I., Hasegawa, M., Nishikawa, S.-I., & Sueishi, K. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00015.2009 · Cited by 54
Genetic medicines for CF: Hype versus reality
Alton, E. W. F. W., Boyd, A. C., Davies, J. C., Gill, D. R., Griesenbach, U., Harrison, P. T., Henig, N., Higgins, T., Hyde, S. C., Innes, J. A., et al. (2016) · Pediatric Pulmonology · doi:10.1002/ppul.23543 · Cited by 53
“part, responsible for the high transduction efficiency of Sendai virus in lungs.(8)”
BackgroundSelf-citationYonemitsu, Y., Matsumoto, T., Itoh, H., Okazaki, J., Uchiyama, M., Yoshida, K., Onimaru, M., Onohara, T., Inoguchi, H., Kyuragi, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.279 · Cited by 52
Gene therapy in cystic fibrosis
Armstrong, D., Cunningham, S., Davies, J. C., & Alton, E. W. F. W. (2014) · Archives of Disease in Childhood · doi:10.1136/archdischild-2012-302158 · Cited by 56
Mogler, M. A., & Kamrud, K. I. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.979798 · Cited by 51
“A recombinant SeV expressing the HIV gag gene has been used alone or in combination with DNA and adenovirus vectors, expressing the same gene, in a prime-boost vaccination regimen [242,244,245].”
BackgroundInfluentialFerrari, S., Uta Griesenbach, D., Shiraki-Iida, T., Shu, T., Hironaka, T., Hou, X., Williams, J. L., Zhu, J., Jeffery, P. K., Geddes, D. M., et al. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302334 · Cited by 53
The development of gene therapy for diseases of the lung
Gill, D. R., Davies, L. A., Pringle, I. A., & Hyde, S. C. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3317-z · Cited by 59
Human neural progenitors derived from integration-free iPSCs for SCI therapy
Liu, Y., Zheng, Y., Li, S., Xue, H., Schmitt, K., Hergenroeder, G. W., Wu, J., Zhang, Y., Kim, D., & Cao, Q. (2017) · Stem Cell Research · doi:10.1016/j.scr.2017.01.004 · Cited by 53
“, 2008), as well as deliver cystic fibrosis transmembrane conductance regulator (CFTR) gene to restore CFTR levels (Yonemitsu et al., 2000; Ferrari et al., 2007).”
BackgroundNagai, Y., & Kato, A. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-06099-5_6 · Cited by 49
Kinoh, H., Inoue, M., Washizawa, K., Yamamoto, T., Fujikawa, S., Tokusumi, Y., Iida, A., Nagai, Y., & Hasegawa, M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302272 · Cited by 48
Development of HVJ Envelope Vector and Its Application to Gene Therapy
Kaneda, Y., Yamamoto, S., & Nakajima, T. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)53012-8 · Cited by 55
Gene delivery systems—gene therapy vectors for cystic fibrosis
Klink, D. T., Schindelhauer, D., Laner, A., Tucker, T. A., Bebok, Z. M., Schwiebert, E. M., Boyd, A., & Scholte, B. J. (2004) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2004.05.042 · Cited by 58
“Recombinant Sendai virus was shown to be very effective in transduction of airway epithelial cells in situ both in mice and ferrets [48,49].”
BackgroundNon-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects
Pringle, I. A., Hyde, S. C., & Gill, D. R. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903055029 · Cited by 53
“If not immediately cleared from the lungs, the GTA must penetrate the mucus to gain access to the surface of the cell and then penetrate the plasma membrane [27].”
BackgroundGazdhar, A., Bilici, M., Pieróg, J., Ayuni, E., Gugger, M., Wetterwald, A., Cecchini, M. G., & Schmid, R. A. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.911 · Cited by 41
Murakami, Y., Ikeda, Y., Yonemitsu, Y., Miyazaki, M., Inoue, M., Hasegawa, M., Sueishi, K., & Ishibashi, T. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.102 · Cited by 40
“The F and HN proteins of SeV mediate viral attachment and penetration (Lamb and Kolakofsky, 1996), and SeV-derived vectors have shown efficient gene transfer with only a few minutes of vector–cell interaction (Yonemitsu et al. , 2000; Masaki et al. , 2001).”
Cytopathogenesis of Sendai Virus in Well-Differentiated Primary Pediatric Bronchial Epithelial Cells
Villenave, R., Touzelet, O., Thavagnanam, S., Sarlang, S., Parker, J. C., Skibiński, G., Heaney, L. G., McKaigue, J. P., Coyle, P. V., Shields, M. D., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00798-10 · Cited by 38
“In view of its respiratory tract tropism, particular attention was paid to its use as a gene therapy vector for lung diseases such as cystic fibrosis (CF) (2, 13, 14, 43).”
BackgroundResultJin, C. H., Kusuhara, K., Yonemitsu, Y., Nomura, A., Okano, S., Takeshita, H., Hasegawa, M., Sueishi, K., & Hara, T. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301877 · Cited by 39
Iwasaki, Y., Negishi, T., Inoue, M., Tashiro, T., Tabira, T., & Kimura, N. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.22830 · Cited by 43
“2), because SeV vector has strong infectivity toward neurons (Li et al., 2000; Yonemitsu et al., 2000), and because it is much easier and less harmful to inject into the alveus than into parenchyma, such as the hippocampus.”
BackgroundNyombayire, J. M., Anzala, O. A., Gazzard, B., Karita, E., Bergin, P. J., Hayes, P., Kopycinski, J. T., Omosa-Manyonyi, G., Jackson, A., Bizimana, J., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw500 · Cited by 43
CFTR gene transfer to human cystic fibrosis pancreatic duct cells using a Sendai virus vector
Rakonczay, Z., Hegyi, P. J., Hasegawa, M., Inoue, M., You, J., Iida, A., Ignáth, I., Alton, E. W. F. W., Uta Griesenbach, D., Óvári, G., et al. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21220 · Cited by 44
“The aim of this study was to assess the utility of a novel recombinant Sendai virus (SeV) vector construct, which has been previously shown to efficiently infect to the airway epithelium (Yonemitsu et al., 2000), as a vector for introducing CFTR into human pancreatic duct cells in vitro.”
BackgroundMethodIwadate, Y., Inoue, M., Saegusa, T., Tokusumi, Y., Kinoh, H., Hasegawa, M., Tagawa, M., Yamaura, A., & Shimada, H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1485 · Cited by 37
“the adenoviral vectors or lipofection (5, 6), and high gene”
BackgroundGenetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
Schneider‐Futschik, E. K. (2019) · Gene Therapy · doi:10.1038/s41434-019-0092-5 · Cited by 38
The Nasal Epithelium as a Factory for Systemic Protein Delivery
Uta Griesenbach, D., Cassady, R. L., Ferrari, S., Fukumura, M., Müller, C. R., Schmitt, E., Zhu, J., Jeffery, P. K., Nagai, Y., Geddes, D. M., et al. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0524 · Cited by 33
“Against this we have previously shown that both human and ovine airway epithelium was efficiently transfected in vitro or ex vivo, respectively [9].”
BackgroundKomaru, A., Ueda, Y., Furuya, A., Tanaka, S., Yoshida, K., Kato, T., Kinoh, H., Harada, Y., Suzuki, H., Inoue, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803845 · Cited by 32
Sendai Virus Vector-Mediated Transgene Expression in the Cochlea in vivo
Kanzaki, S., Shiotani, A., Inoue, M., Hasegawa, M., & Ogawa, K. (2006) · Audiology and Neurotology · doi:10.1159/000097798 · Cited by 32
Prospects and problems of gene therapy: an update
Górecki, D. C. (2001) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.6.2.187 · Cited by 33
“While some of these new vectors may have considerable potential, it is too early to ascertain this yet [46-48].”
BackgroundOvercoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies
Nath, S. C., Menendez, L., & Friedrich Ben-Nun, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316929 · Cited by 35
“Although both methods have low reprogramming efficiency, Sendai virus-mediated reprogramming has been used for several clinical applications, notably, in cystic fibrosis, the AIDS vaccine, and other iPSC replacement therapies [29–33].”
MethodPiao, W., Wang, H., Inoue, M., Hasegawa, M., Hamada, H., & Huang, J. (2010) · Angiogenesis · doi:10.1007/s10456-010-9169-x · Cited by 32
“Sendai virus is considered as no-pathogen to human, and efficient gene transduction into various primary cultured cells and tissues by recombinant virus vector has been reported [12–17].”
BackgroundGraepler, F. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i44.6910 · Cited by 31
Mechanism of efficient transfection of the nasal airway epithelium by hypotonic shock
Lemoine, J. L., Farley, R., & Huang, L. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302548 · Cited by 30
Inoue, M., Tokusumi, Y., Ban, H., Shirakura, M., Kanaya, T., Yoshizaki, M., Hironaka, T., Nagai, Y., Iida, A., & Hasegawa, M. (2004) · Journal of Gene Medicine · doi:10.1002/jgm.597 · Cited by 34
“sheeps [2], the vascular system of rabbits [35] and the”
BackgroundIkeda, Y., Yonemitsu, Y., Sakamoto, T., Ishibashi, T., Ueno, H., Kato, A., Nagai, Y., Fukumura, M., Inomata, H., Hasegawa, M., et al. (2002) · Experimental Eye Research · doi:10.1006/exer.2002.1177 · Cited by 29
Wiegand, M. A., Savellini, G. G., Gandolfo, C., Papa, G., Kaufmann, C. M., Felder, E., Ginori, A., Disanto, M. G., Spina, D., & Cusi, M. G. (2017) · Journal of Virology · doi:10.1128/jvi.02298-16 · Cited by 32
“Because of this and the natural ability of the Sendai vector to efficiently infect respiratory epithelium (22, 23), we decided to evaluate this new SeV76 vaccine after administration by the mucosal or intramuscular immunization route.”
BackgroundValidation of recombinant Sendai virus in a non-natural host model
Uta Griesenbach, D., McLachlan, G., Owaki, T., Somerton, L., Shu, T., Baker, A., Tennant, P. A., Gordon, C., Vrettou, C., Baker, E., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.131 · Cited by 30
Primary replication of a recombinant Sendai virus vector in macaques
Kano, M., Matano, T., Kato, A., Nakamura, H. K., Takeda, A., Suzaki, Y., Ami, Y., Terao, K., & Nagai, Y. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-6-1377 · Cited by 29
Shoji, F., Yonemitsu, Y., Okano, S., Yoshino, I., Nakagawa, K., Nakashima, Y., Hasegawa, M., Sugimachi, K., & Sueishi, K. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301847 · Cited by 28
“We recently reported that recombinant Sendai virus (SeV), a new gene transfer agent, produce log-ordersReceived 26 February 2002; accepted 21 June 2002 Correspondence: Y Yonemitsu, Division of Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University…”
Background
Metadata
- Authors
- Yonemitsu, Y., Kitson, C., Ferrari, S., Farley, R., Griesenbach, U., Judd, D., Steel, R., Scheid, P., Zhu, J., Jeffery, P. K., Kato, A., Hasan, M. K., Nagai, Y., Masaki, I., Fukumura, M., Hasegawa, M., Geddes, D. M., & Alton, E. W. F. W.
- Affiliations
- Imperial College London (GB)
- National Institute of Infectious Diseases (JP)
- Kyushu University (JP)
- ID Pharma (Japan) (JP)
- Corresponding author
- Alton, Eric W.F.W.
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2000-09
- Volume
- 18
- Issue
- 9
- Pages
- 970-973
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1553961669
- Cited by
- 244
- References
- 25
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 10 · 2016: 11 · 2015: 5 · 2014: 7 · 2013: 11 · 2012: 8
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- cystic fibrosis gene therapy, nasal epithelial cells, cationic liposomes, ferrets, mice
- MeSH terms
- Adenoviridae, Animals, Bronchi, Cell Line, Cells, Cultured, Cystic Fibrosis, Dogs, Dose-Response Relationship, Drug, Epithelium, Female, Ferrets, Genetic Vectors, Humans, Liposomes, Luciferases, Lung, Male, Mice, Inbred BALB C, Mucous Membrane, Nasal Mucosa, Receptors, Cell Surface, Sheep, Time Factors, Trachea, Transfection, Gene Transfer Techniques, Respirovirus, COS Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.